KALA BIO (KALA)
NASDAQ:KALA
Want to see KALA full AI Analyst Report?
Top Page
KALA BIO
(NASDAQ:KALA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▲(383.87% Upside)
Action:Reiterated
Date:06/17/26
The score is primarily held down by extremely weak fundamentals—zero revenue, ongoing losses, and continued cash burn—despite improved leverage with debt reduced to zero. Technical indicators also lean bearish with the price below key moving averages and a negative MACD, while valuation is constrained by ongoing losses (negative P/E) and no dividend support.
Positive Factors
Leverage eliminated (debt = 0)
Debt reduced to zero materially lowers near-term refinancing and interest risks, improving financial flexibility to fund clinical programs. This durable balance sheet improvement reduces insolvency risk and extends runway versus prior years, remaining relevant over the next several quarters.
Negative Factors
Zero revenue & persistent losses
Zero revenue eliminates any internal cash generation and removes gross-profit buffers, leaving operations fully reliant on external financing. Persistent net losses weaken sustainable funding sources and make long-term planning dependent on successful financing or milestone events over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Leverage eliminated (debt = 0)
Debt reduced to zero materially lowers near-term refinancing and interest risks, improving financial flexibility to fund clinical programs. This durable balance sheet improvement reduces insolvency risk and extends runway versus prior years, remaining relevant over the next several quarters.
Read all positive factors
KALA BIO (KALA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$58.37M
Dividend YieldN/A
Average Volume (3M)1.94M
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue GrowthN/A
EPS Growth66.47%
CountryUS
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.90
Shares Outstanding18,589,832
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)32.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.08
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.12K
Enterprise Value/Ebitda-3.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-26.5
Revenue Forecast (FY)N/A
KALA BIO Business Overview & Revenue Model
Company Description
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating...
How the Company Makes Money
null...
KALA BIO Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
34
Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.89M | 11.24M |
| Gross Profit | -54.00K | 0.00 | -259.00K | -303.00K | 1.33M | 7.14M |
| EBITDA | -17.22M | -23.39M | -32.47M | -36.08M | -36.70M | -131.96M |
| Net Income | -19.65M | -26.98M | -38.51M | -42.20M | -44.82M | -142.60M |
Balance Sheet | ||||||
| Total Assets | 12.32M | 9.49M | 55.48M | 55.95M | 86.82M | 139.43M |
| Cash, Cash Equivalents and Short-Term Investments | 8.76M | 7.56M | 51.18M | 50.90M | 70.50M | 92.14M |
| Total Debt | 0.00 | 0.00 | 32.25M | 36.32M | 42.95M | 80.19M |
| Total Liabilities | 1.56M | 2.49M | 43.15M | 48.45M | 67.85M | 122.62M |
| Stockholders Equity | 10.76M | 7.00M | 12.33M | 7.50M | 18.97M | 16.80M |
Cash Flow | ||||||
| Free Cash Flow | -26.06M | -31.99M | -29.59M | -28.54M | -79.22M | -109.12M |
| Operating Cash Flow | -26.06M | -31.99M | -29.38M | -27.93M | -78.91M | -108.23M |
| Investing Cash Flow | -7.03M | -15.00K | -208.00K | -429.00K | 62.72M | 70.80M |
| Financing Cash Flow | -7.38M | -11.62M | 29.88M | 8.51M | -7.94M | 42.55M |
KALA BIO Technical Analysis
Neutral
0.62
Price Trends
4.91
Negative
10.99
Negative
102.99
Negative
Market Momentum
-0.55
Negative
42.78
Neutral
74.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KALA, the sentiment is Neutral. The current price of 0.62 is below the 20-day moving average (MA) of 2.43, below the 50-day MA of 4.91, and below the 200-day MA of 102.99, indicating a neutral trend. The MACD of -0.55 indicates Negative momentum. The RSI at 42.78 is Neutral, neither overbought nor oversold. The STOCH value of 74.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KALA.
KALA BIO Risk Analysis
KALA BIO disclosed 67 risk factors in its most recent earnings report. KALA BIO reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
KALA BIO Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $84.95M | -11.61 | -28.75% | ― | 2.08% | -106.57% | |
54 Neutral | $26.51M | 146.78 | 0.27% | ― | 82.13% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $26.73M | -4.74 | -15.41% | ― | -30.75% | -1056.69% | |
46 Neutral | $40.62M | -0.99 | -57.16% | ― | 673.54% | 23.14% | |
44 Neutral | $58.37M | -1.18 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
KALA
KALA BIO
3.61
-208.39
-98.30%
RMTI
Rockwell Med
0.64
-0.25
-28.09%
TXMD
TherapeuticsMD
1.95
0.86
78.90%
SCYX
SCYNEXIS
4.05
-1.91
-32.00%
CPIX
Cumberland Pharmaceuticals
5.72
1.37
31.49%
KALA BIO Corporate Events
Regulatory Filings and ComplianceStock Split
KALA BIO Implements 1-for-50 Reverse Stock Split
Neutral
May 7, 2026
KALA BIO on May 7, 2026 filed a Certificate of Amendment in Delaware to implement a 1-for-50 reverse stock split of its common stock, effective May 8, 2026, following shareholder approval granted at a meeting held January 30, 2026. The move consol...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.